Your browser doesn't support javascript.
loading
Tuberculosis (TB) treatment challenges in TB-diabetes comorbid patients: a systematic review and meta-analysis.
Khattak, Mahnoor; Rehman, Anees Ur; Muqaddas, Tuba; Hussain, Rabia; Rasool, Muhammad Fawad; Saleem, Zikria; Almalki, Mesfer Safar; Alturkistani, Samar Adel; Firash, Shuruq Zuhair; Alzahrani, Oseid Mohammed; Bahauddin, Ammar Abdulraheem; Abuhussain, Safa Almarzooky; Najjar, Muath Fahmi; Elsabaa, Hossameldeen Mahmoud Ali; Haseeb, Abdul.
Afiliación
  • Khattak M; Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
  • Rehman AU; Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
  • Muqaddas T; Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
  • Hussain R; Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia, Penang, Malaysia.
  • Rasool MF; Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
  • Saleem Z; Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
  • Almalki MS; Security Forces Hospital, Ministry of Interior, Makkah, Saudi Arabia.
  • Alturkistani SA; Security Forces Hospital, Ministry of Interior, Makkah, Saudi Arabia.
  • Firash SZ; Department of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Alzahrani OM; Security Forces Hospital, Ministry of Interior, Makkah, Saudi Arabia.
  • Bahauddin AA; Department of Pharmacology and Toxicology, College of Pharmacy, Taibah University, Madinah, Saudi Arabia.
  • Abuhussain SA; Department of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Najjar MF; Department of Clinical Pharmacy, Al Rayan Private College of Health Sciences and Nursing, Madinah, Saudi Arabia.
  • Elsabaa HMA; Department of Clinical Pharmacy, Al Rayan Private College of Health Sciences and Nursing, Madinah, Saudi Arabia.
  • Haseeb A; Department of Clinical Pharmacy, Al Rayan Private College of Health Sciences and Nursing, Madinah, Saudi Arabia.
Ann Med ; 56(1): 2313683, 2024 Dec.
Article en En | MEDLINE | ID: mdl-38346381
ABSTRACT

BACKGROUND:

The Directly Observed Treatment-Short Course (DOTS) Programme was implemented by WHO and includes a combination of four anti-tuberculosis (TB) drugs (isoniazid, pyrazinamide, ethambutol and rifampicin) for a period of six months to eradicate the TB infection completely. Diabetes mellitus (DM) is recognized as one of a strong contributor of TB according to World Health Organization (WHO). The presence of diabetes mellitus type 2 (DM type 2) makes TB treatment complicated. Thus, the objective of the current meta-analysis was to identify and quantify the impact of type 2 DM on treatment outcomes of TB patients treated under the DOTS Programme.

METHODS:

This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Through a systematic review of relevant literature, we focused on studies investigating treatment outcomes including extended treatment duration and recurrence for individuals with both TB and DM undergoing DOTS therapy. The extracted information included study designs, sample sizes, patient characteristics and reported treatment results.

RESULTS:

In 44 studies from different parts of the world, the pooled HR for the impact of DM on extended treatment duration and reoccurrence were HR 0.72, 95% CI 0.56-0.83, p < .01 and HR 0.93, 95% CI 0.70-1.04, p = .08, respectively. The pooled HR for impact of DM on composite TB treatment outcomes was calculated as 0.76 (95% CI 0.60-0.87), p < .01 with an effect size of 41.18. The heterogeneity observed among the included studies was moderate (I2 = 55.79%).

CONCLUSIONS:

A negative impact of DM was found on recurrence and extended treatment duration in TB patients treated with DOTS therapy. DM type 2 is responsible for the TB treatment prolongation and TB recurrence rates. By implementing effective management strategies and advancing research, the challenges can be mitigated, arising due to the complex interaction between DM and TB.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tuberculosis / Terapia por Observación Directa / Diabetes Mellitus Tipo 2 / Antituberculosos Tipo de estudio: Guideline / Prognostic_studies / Systematic_reviews Límite: Female / Humans / Male Idioma: En Revista: Ann Med Asunto de la revista: MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Pakistán Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tuberculosis / Terapia por Observación Directa / Diabetes Mellitus Tipo 2 / Antituberculosos Tipo de estudio: Guideline / Prognostic_studies / Systematic_reviews Límite: Female / Humans / Male Idioma: En Revista: Ann Med Asunto de la revista: MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Pakistán Pais de publicación: Reino Unido